

- SK-OV-3
- ◆— HEY
- OVCAR-3
- ◇— MDA-468
- A375-M
- HS294T
- ▲— A431

FIG. 1






FIG. 2



---□--- HEY
—◆— OVCAR-3
—□— C-1
—◇— SKOV-3
—■— PANC-1
—□— 769-P
—▲— 786-O
—△— A498

FIG. 3



—□— JURKAT
—◆— KG-1
—□— FEH
—◇— NALM-6

FIG. 4




FIG. 5




FIG. 6



1 2 3 4 5 6 7 8 9 10 11 12



FIG. 7



FIG. 8



Dose: 0.2 ml

ACETONE
4 Weeks

Mouse # 133



FIG. 9A

Dose: 0.2 ml

ACETONE
8 Weeks

Mouse # 150




FIG. 9B



Dose: 100 nmol

DMBA
4 Weeks

Mouse # 130




FIG. 9C

Dose: 100 nmol

DMBA
8 Weeks

Mouse # 149



FIG. 9D



Dose: 0.3 mg

Compound # 35
4 Weeks

Mouse # 136



FIG. 9E



Dose: 0.3 mg



Compound # 35 + DMBA
8 Weeks

Mouse # 140



FIG. 9F








FIG. 12




FIG. 13



Control(-) C57		Control(+) C57 tumor		DMBA 100 nmol (4 weeks)				35(0.3) + DMBA 100 nmol (4 weeks)			
WT	MUT	WT	MUT	WT	MUT	WT	MUT	WT	MUT	WT	MUT



110 kb

FIG. 14





FIG. 15




FIG. 16




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 18D




FIG. 18E






FIG. 18F




- ☐ SUB G-0 (0.9%)
- ☒ G-1 (47.9%)
- ☒ S (36.1%)
- ☒ G-2 + M (6.8%)

FIG. 19A



- ☐ SUB G-0 (1.6%)
- ☒ G-1 (57.4%)
- ☒ S (26.8%)
- ☒ G-2 + M (8.8%)

FIG. 19B



- 1: Untreated
- 2: TNF (100pM)
- 3: F035 (1μg/ml)
- 4: TNF + F035 (1μg/ml)
- 5: F035 (2μg/ml)
- 6: TNF + F035 (2μg/ml)
- 7: F094 (1μg/ml)
- 8: TNF + F094 (1μg/ml)
- 9: F094 (2μg/ml)
- 10: TNF + F094 (2μg/ml)

FIG. 20





FIG. 21





FIG. 22





FIG. 23



STRUCTURE OF ELLIPTOSIDES:

ELLIPTOSIDE E IF R=OH

ELLIPTOSIDE A IF R=H




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 37







FIG. 38






FIG. 42




FIG. 43



38 / 43








FIG. 44




FIG. 45A




FIG. 45B



FIG. 46A




FIG. 46B




FIG. 46C





FIG. 46D






FIG. 47




FIG. 48




FIG. 49





time (h) 0 4 6
   → Cytochrome c

FIG. 50




FIG. 51A




FIG. 51B




FIG. 52A

Rabbit IgG	-	-	-	-	-	+
anti-p65	-	-	-	-	+	-
Cold wt	-	-	-	+	-	-
Cold mut	-	-	+	-	-	-
TNF	-	+	+	+	+	+




FIG. 52B



I κ B




FIG. 53A

p65




FIG. 53B




FIG. 54A




FIG. 54B





FIG. 54C



Inducers of NF-kB

FIG. 55A






FIG. 55B



IC₅₀ Values


HPLC Separation of the Avicins in F094

0.331-0.407 $\mu\text{g/ml}$



Avicin D

0.320-0.326 $\mu\text{g/ml}$



Avicin G

0.160-0.181 $\mu\text{g/ml}$

FIG. 56




FIG. 57




FIG. 58



FIG. 59A




FIG. 59B





FIG. 59C




FIG. 60A




FIG. 60B




FIG. 60C




FIG. 61




FIG. 62

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.